Stock ARPO AERPIO PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Aerpio Pharmaceuticals

Equities

ARPO

US00810B1052

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
GL
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
GL
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
GL
Aerpio Pharmaceuticals : Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
GL
AADI BIOSCIENCE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Aerpio Pharmaceuticals : Aadi Bioscience Corporate Overview
PU
Aerpio Pharmaceuticals : ASSET PURCHASE AGREEMENT (Form 8-K)
PU
AERPIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Aerpio Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)
PU
AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)
PU
Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update
AQ
Aerpio Pharmaceuticals : Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa (Form 8-K)
PU
AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
AQ
Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting (Form 8-K)
PU
AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
GL
AERPIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerpio Pharmaceuticals, Inc. - ARPO
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARPO Stock
  4. News Aerpio Pharmaceuticals
  5. Press Releases